A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 490
- Registration Number
- NCT01059773
InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 1085
- Registration Number
- NCT01026285
A Study to Compare Patient-controlled Pain Medications Delivered Either Through the Skin or Intravenously
Phase 4
Completed
- Conditions
- PainAnalgesia, Patient-ControlledPain, Postoperative
- Interventions
- Drug: IONSYS (fentanyl HCl) Iontophoretic TransdermalSystemDrug: IV Morphine Patient-Controlled Analgesia (IV PCA)
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 657
- Registration Number
- NCT00996177
Placebo-controlled Trial With OROS Hydromorphone Hydrochloride to Treat Patients With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee
Phase 3
Completed
- Conditions
- PainOsteoarthritis, HipOsteoarthritis, Knee
- Interventions
- Drug: PlaceboDrug: OROS hydromorphone HCl
- First Posted Date
- 2009-09-21
- Last Posted Date
- 2014-04-25
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 288
- Registration Number
- NCT00980798
Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD
Phase 2
Completed
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2015-01-15
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 163
- Registration Number
- NCT00908232
A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients
Phase 2
Completed
- Conditions
- HIV InfectionHIVAcquired Immunodeficiency Syndrome
- Interventions
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2013-01-14
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 157
- Registration Number
- NCT00903682
A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder
Phase 3
Completed
- Conditions
- Attention Deficit/ Hyperactivity Disorder
- Interventions
- First Posted Date
- 2008-07-14
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 279
- Registration Number
- NCT00714688
Observational Study to Assess Outcomes During Antipsychotic Treatment With Paliperidone ER or Other Oral Antipsychotics
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 3064
- Registration Number
- NCT00696813
A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 462
- Registration Number
- NCT00645099
An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 294
- Registration Number
- NCT00566631
© Copyright 2025. All Rights Reserved by MedPath